|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock option (right to buy) | $ 3.77 (2) | 10/15/2015 | D | 10,000 | (3) | 11/30/2016 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 2.95 | 10/15/2015 | D | 10,000 | (3) | 12/07/2017 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 1.37 | 10/15/2015 | D | 10,000 | (3) | 12/17/2019 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 4.43 | 10/15/2015 | D | 10,000 | (3) | 12/16/2020 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 6.21 | 10/15/2015 | D | 10,000 | (3) | 12/14/2021 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 4.52 | 10/15/2015 | D | 10,000 | (3) | 12/14/2022 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 3.46 | 10/15/2015 | D | 10,000 | (3) | 12/13/2023 | Common Stock | 10,000 | (3) | 0 | D | ||||
Stock option (right to buy) | $ 3.7 | 10/15/2015 | D | 10,000 | (3) | 12/12/2024 | Common Stock | 10,000 | (3) | 0 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Cardinale Lawrence C C/O SYNERGETICS USA, INC. 3845 CORPORATE CENTRE DRIVE O'FALLON, MO 63368 |
X |
/s/ Lawrence C. Cardinale | 10/15/2015 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Shares tendered for an offer price of $6.50 per share in cash (the "Cash Consideration") plus one non-transferable contractual contingent value right per share (each, a "CVR"), which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate, net to the holder in cash, upon the achievement of certain specified milestones within an agreed upon time period (less any applicable withholding taxes and without interest), pursuant to the tender offer consummated on September 16, 2015 according to the terms of the Agreement and Plan of Merger (the "Merger" Agreement"), dated as of September 1, 2015, by and among Valeant Pharmaceuticals International, Blue Subsidiary Corp. and Synergetics USA, Inc. |
(2) | The Form 4 reporting the award of the stock option on November 30, 2006 reported an exercise price of $3.89 in error. |
(3) | Pursuant to the terms of the Merger Agreement, on October 15, 2015, each option outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) was canceled in exchange for (i) a cash payment equal to the product of (A) the number of shares underlying the option and (B) the difference between the Cash Consideration and the exercise price of the option; and (ii) one CVR for each share underlying the option, in each case without interest and subject to any applicable tax withholding. |